Active	Status	Sponsor type	Region	Phase	Filter
5 Active 1 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Wang, Wenxiang
LIBRETTO-432, NCT04819100 / 2020-005191-35: A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)	Recruiting	3	170	Europe, Canada, Japan, US, RoW	Selpercatinib, LY3527723, LOXO-292, Placebo	Loxo Oncology, Inc., Eli Lilly and Company	Carcinoma, Non-Small-Cell Lung	05/27	08/32
NCT04767295: A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC)	Recruiting	2	28	RoW	Camrelizumab, Albumin Paclitaxel, Carboplatin, SHR1210	Hunan Cancer Hospital, Jiangsu HengRui Medicine Co., Ltd.	Esophageal Squamous Cell Carcinoma	03/23	03/23
TVATLC01, NCT03807102: Trial of Tumor Vaccine Used for Adjuvant Therapy in Post Radical Operation Patients With Lung Cancer	Not yet recruiting	1/2	30	RoW	Tumor Vaccine	Yongchang Zhang, Shanghai Houchao Biotechnology Co., Ltd	Lung Cancer	01/25	01/26
NCT06443684: A Study of Molecular Residual, Dynamic Monitoring and Recurrence of Stage III Driver Mutated NSCLC	Recruiting	N/A	305	RoW	MRD	Shanghai Chest Hospital	Non Small Cell Lung Cancer	03/25	03/26
MOTION-NSCLC, NCT06709274: Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC	Not yet recruiting	N/A	342	RoW	Osimertinib, Alectinib, TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy	Guangdong Association of Clinical Trials, Nanjing Geneseeq Technology Inc.	Non-Small Cell Lung Cancer	01/29	01/32